Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
•
Non-Tubercular Mycobacteria
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
Answer from: at Academic Institution
No, not at this time. Intriguing, but not sure we know enough yet.
Sign in or Register to read more
Answer from: at Academic Institution
I ordered it once but it didn’t help in the diagnosis. The patient expired from multiple organ dysfunction syndrome (MODS) and sepsis. It is an expensive test, so I won’t be ordering it routinely.
Sign in or Register to read more
16531
16652
Related Questions
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
What is your approach to duration of antibiotic therapy for treatment of a bacterial lung abscess?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
Is there any utility to trending Histoplasma serology titers to guide duration of therapy or treatment response for pulmonary histoplasmosis with negative urine antigen?
Have you used Karius to aid in the diagnosis of a non-resolving pneumonia, with negative bronchoscopy, biopsy, and other infectious work up in an immunocompetent patient?
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Have you incorporated the use of steroids for patients with severe community-acquired pneumonia?